PDR10 Antibody

What are P2RY10 and PDE10A antibodies, and how do they differ?

P2RY10 antibodies target the P2Y10/P2RY10 receptor, which belongs to the G protein-coupled receptor family involved in cellular signaling pathways. These antibodies, such as the Mouse Anti-Human P2Y10/P2RY10 Monoclonal Antibody (Clone #639329), are specifically designed to recognize and bind to the human P2Y10/P2RY10 protein (Accession #O00398) . They are primarily utilized in flow cytometry and immunohistochemistry applications.

In contrast, PDE10A antibodies target Phosphodiesterase 10A, a striatum-enriched phosphodiesterase. PDE10A IgG has been identified as a novel biomarker of neurologic paraneoplastic autoimmunity. These antibodies produce basal ganglia-predominant synaptic staining patterns when applied to murine brain tissue using indirect immunofluorescence techniques .

The primary difference lies in their target proteins and neurological implications - P2RY10 antibodies target receptors involved in cellular signaling, while PDE10A antibodies have specific relevance to neurological autoimmune conditions.

What experimental applications are most suitable for P2RY10 antibodies?

P2RY10 antibodies demonstrate optimal performance in several experimental applications:

• Flow Cytometry: Mouse Anti-Human P2Y10/P2RY10 antibodies have been validated for detecting P2Y10/P2RY10 in transfected HEK293 cell lines. The protocol typically involves staining with the primary antibody followed by an Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody .

• Immunohistochemistry (IHC): These antibodies effectively detect P2Y10/P2RY10 in fixed paraffin-embedded tissue sections, particularly in human thymus samples. Recommended protocol includes using 15 μg/mL of antibody with heat-induced epitope retrieval and visualization using HRP Polymer Detection systems .

• Cellular Research: P2RY10 antibodies have been employed in studies investigating MUC5AC production via the TACE-EGFR-ERK pathway in airway epithelial cells, demonstrating their utility in elucidating receptor-independent cellular mechanisms .

For optimal results, antibody dilutions should be determined experimentally for each specific application and cellular/tissue system.

How are PDE10A antibodies used to study neurological disorders?

PDE10A antibodies serve as valuable tools in studying neurological disorders through several methodological approaches:

• Diagnostic Biomarker Applications: PDE10A IgG has been identified as a novel biomarker for neurologic paraneoplastic autoimmunity. Patient specimens (sera and CSF) producing basal ganglia-predominant synaptic staining of murine brain tissue by indirect immunofluorescence can be evaluated for the presence of these antibodies .

• Identification Methodology: The autoantigen can be identified through a systematic approach including immunoprecipitation, mass spectrometry, antigen-specific recombinant Western blot, cell-based assays, and immune absorption experiments .

• Clinical Correlation Studies: Researchers can correlate the presence and titer of PDE10A antibodies with specific neurological presentations, enhancing understanding of the pathophysiology of autoimmune neurological disorders.

• Antibody Specificity Verification: Western blot techniques using commercially available recombinant human PDE10A protein (expected MW 116 kDa) can confirm antibody immunoreactivity. Additionally, absorption tests using patient sera incubated with recombinant PDE10A can validate specificity through immunofluorescence assays .

These methodologies provide researchers with robust tools to investigate the role of PDE10A in neurological pathologies.

What are the critical considerations for designing experiments with P2RY10 antibodies?

When designing experiments with P2RY10 antibodies, researchers should address the following methodological considerations:

• Antibody Validation: Confirm antibody specificity using both positive controls (P2RY10-expressing cells like transfected HEK293 cells) and negative controls (isotype control antibodies such as Mouse IgG2B). This validation is crucial for establishing experimental reliability .

• Signal Verification Strategy: Implement a dual-verification approach by using:

  • Multiple detection methods (flow cytometry and IHC)

  • Different antibody clones if available

  • Genetic validation (knockdown/knockout of target)

• Protocol Optimization Matrix:

• Sample Preparation Considerations: For flow cytometry, maintain cell viability above 95% and use proper compensation controls. For IHC, heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic is critical before primary antibody incubation .

These design elements ensure rigorous experimental controls and reproducible results when working with P2RY10 antibodies.

How should I optimize Western blot protocols for PDE10A antibody detection?

Optimizing Western blot protocols for PDE10A antibody detection requires systematic attention to multiple parameters:

• Sample Preparation Protocol:

  • Prepare protein extracts under non-denaturing conditions if conformational epitopes are targeted

  • Include protease inhibitors to prevent degradation of PDE10A (116 kDa)

  • Use appropriate lysis buffers compatible with neuronal tissues

• Electrophoresis and Transfer Parameters:

  • For high molecular weight PDE10A (116 kDa), use lower percentage gels (7-8%)

  • Extend transfer time for large proteins (2-3 hours or overnight at 30V)

  • Use PVDF membranes for better protein retention

• Blocking and Antibody Incubation Optimization:

  • Test multiple blocking agents (5% non-fat milk, 5% BSA)

  • Optimize primary antibody dilution (start with manufacturer's recommendation)

  • Incubate primary antibody overnight at 4°C for improved specificity

• Validation Approaches:

  • Use commercially available recombinant human PDE10A protein (≥48% purity) as a positive control

  • Include a molecular weight marker to confirm the expected 116 kDa band

  • Perform absorption tests by pre-incubating antibodies with recombinant PDE10A to confirm specificity

• Troubleshooting Strategy:

  • For weak signals: increase antibody concentration or protein loading

  • For multiple bands: optimize washing steps and antibody dilution

  • For background issues: increase blocking time or detergent concentration in wash buffers

This methodical approach ensures optimal detection of PDE10A while minimizing non-specific signals and false positives.

What controls are essential when performing flow cytometry with P2RY10 antibodies?

When performing flow cytometry with P2RY10 antibodies, a comprehensive control strategy is essential for generating reliable and interpretable data:

• Primary Control Panel:

  • Isotype Control: Mouse IgG2B Isotype Control Antibody (e.g., Catalog # MAB0041) is critical for determining background binding and setting gates properly

  • Fluorescence Minus One (FMO): Include all fluorophores except anti-P2RY10 to account for spectral overlap

  • Unstained Cells: Establish baseline autofluorescence of the cell population

  • Single-Stained Controls: For compensation when using multiple fluorophores

• Biological Validation Controls:

  • Positive Control: HEK293 cells transfected with P2RY10 and eGFP serve as an ideal positive control system

  • Negative Control: Non-transfected HEK293 cells or cells known not to express P2RY10

  • Expression Gradient: When possible, include cells with varying levels of P2RY10 expression

• Technical Controls for Quality Assurance:

  • Viability Dye: Include a viability marker to exclude dead cells which can bind antibodies non-specifically

  • Fc Block: Pre-treat samples with Fc blocking reagent to reduce non-specific binding

  • Secondary Antibody Only: Control for non-specific binding of secondary antibody

• Analysis Controls:

  • Consistent Gating Strategy: Establish and document a consistent gating hierarchy

  • Fluorescence Intensity Standards: Use calibration beads to standardize fluorescence intensity measurements

  • Matched Instrument Settings: Maintain consistent PMT voltages between experiments

Implementation of this control framework ensures that observed signals are specifically attributable to P2RY10 expression rather than technical artifacts or non-specific binding.

How can I establish a T-cell activation bioassay system to evaluate PD-1 antibody efficacy similar to REGN2810 studies?

Establishing a T-cell activation bioassay system for evaluating PD-1 antibody efficacy requires a sophisticated experimental setup similar to that used in REGN2810 studies:

• Cell Engineering Components:

  • Engineer Jurkat T cells to express full-length human PD-1 protein and an AP-1-driven luciferase reporter (Jurkat/AP-1-Luc/hPD-1)

  • Generate antigen-presenting cell (APC)-like HEK293 cells by lentiviral transduction of human CD20 and human PD-L1

  • Develop a system for T-cell receptor activation using an anti-CD3 x anti-CD20 bispecific antibody

• Assay Protocol Implementation:

  • Plate 50,000 Jurkat/AP-1-Luc/hPD-1 cells with 10,000 HEK293/hCD20/hPD-L1 cells per well in a 96-well format

  • Establish a dose-response curve for the anti-CD3 x anti-CD20 bispecific antibody

  • Test serially diluted test antibody in the presence of a fixed concentration (100 pmol/L) of the bispecific antibody

  • Incubate plates at 37°C for 4-6 hours

  • Add ONE-Glo luciferase substrate and measure Relative Luminescence Units (RLU)

• Data Analysis Strategy:

  • Calculate percent inhibition by comparing luminescence in PD-L1-positive versus PD-L1-negative conditions

  • Determine EC50 values to quantify antibody potency

  • Normalize data to positive (maximal activation) and negative (maximal inhibition) controls

• Validation Approach:

  • Confirm that the antibody does not cause TCR-independent T-cell activation using human PBMC cytokine release assays

  • Include super-agonist anti-CD28 or anti-CD3 antibodies as positive controls

  • Verify that immobilized antibody does not result in significant cytokine release from human PBMCs

This methodological framework provides a robust system for evaluating the functional efficacy of PD-1 antibodies in blocking the PD-1/PD-L1 interaction and enhancing T-cell responses.

What techniques should I use to characterize the binding specificity and affinity of novel PDR10-related antibodies?

To characterize binding specificity and affinity of novel PDR10-related antibodies (P2RY10 or PDE10A), implement the following comprehensive analytical approach:

• Binding Specificity Assessment:

  • Western Blot Validation: Use purified recombinant protein (e.g., recombinant human PDE10A) to confirm antibody recognition of the target protein at the expected molecular weight (116 kDa for PDE10A)

  • Immunoprecipitation Analysis: Perform IP followed by mass spectrometry for unbiased target confirmation

  • Absorption Experiments: Incubate sera/antibodies with recombinant target protein overnight followed by immunofluorescence assay to demonstrate specificity through signal depletion

  • Cross-Reactivity Testing: Evaluate antibody against related proteins to confirm target selectivity

• Affinity Determination Methodologies:

  • Surface Plasmon Resonance (SPR): Determine kon, koff, and KD values

  • Bio-Layer Interferometry (BLI): Alternative to SPR for real-time binding analysis

  • Enzyme-Linked Immunosorbent Assay (ELISA): Develop titration curves to estimate relative affinity

  • Flow Cytometry-Based Titration: Using transfected cell lines expressing target proteins at defined levels

• Functional Characterization:

  • Cell-Based Bioassays: Evaluate biological activity in relevant cellular systems

  • Epitope Mapping: Determine the specific binding region using peptide arrays or mutational analysis

  • Competition Assays: Assess ability to compete with natural ligands or other antibodies

• Data Integration Matrix:

This multifaceted approach provides comprehensive characterization of antibody specificity and binding properties, ensuring reliable performance in downstream applications.

How can I effectively use PDE10A antibodies for studying neurological paraneoplastic syndromes?

Effectively using PDE10A antibodies for studying neurological paraneoplastic syndromes requires a systematic research approach:

• Patient Sample Processing Protocol:

  • Collect both sera and CSF from patients with suspected neurological paraneoplastic syndromes

  • Process samples consistently, with prompt separation and storage at -80°C

  • Document detailed clinical information including neurological symptoms, tumor history, and response to treatments

• Screening Methodology:

  • Indirect Immunofluorescence: Apply patient specimens to murine brain tissue sections to identify basal ganglia-predominant synaptic staining patterns characteristic of PDE10A antibodies

  • Cell-Based Assays: Develop cell-based assays using cells expressing PDE10A for targeted screening

  • ELISA/Immunoblotting: Use recombinant PDE10A protein for quantitative antibody detection

• Confirmation Strategy:

  • Antigen-Specific Recombinant Western Blot: Use commercial recombinant human PDE10A protein (≥48% purity, 116 kDa) to confirm antibody reactivity

  • Absorption Tests: Incubate patient sera with recombinant PDE10A overnight, then test by immunofluorescence to demonstrate signal reduction

  • Immunoprecipitation and Mass Spectrometry: For definitive autoantigen identification

• Clinical-Immunological Correlation Analysis:

  • Symptom Mapping: Correlate antibody titers with specific neurological manifestations

  • Treatment Response Monitoring: Track antibody levels in relation to immunotherapy responses

  • Tumor Association Studies: Investigate relationships between antibody presence and specific cancer types

• Research Documentation Framework:

  • Maintain standardized clinical assessment scales for neurological symptoms

  • Document radiological findings, particularly striatal abnormalities

  • Track longitudinal changes in antibody titers during disease course and treatment

This comprehensive approach enables researchers to effectively utilize PDE10A antibodies for both diagnostic purposes and mechanistic studies of neurological paraneoplastic syndromes, advancing understanding of these immune-mediated neurological disorders.

How should I address inconsistent immunohistochemistry results with P2RY10 antibodies?

When encountering inconsistent immunohistochemistry results with P2RY10 antibodies, implement this systematic troubleshooting approach:

• Sample Preparation Optimization:

  • Fixation Assessment: Overfixation can mask epitopes; optimize fixation time (4-24 hours in 10% neutral buffered formalin)

  • Antigen Retrieval Evaluation: Test different methods (heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic is recommended for P2RY10)

  • Section Thickness Standardization: Maintain consistent section thickness (4-5 μm optimal)

• Antibody Protocol Refinement:

  • Titration Series: Test multiple antibody concentrations (5-20 μg/mL) around the recommended 15 μg/mL

  • Incubation Conditions: Optimize temperature and duration (1 hour at room temperature vs. overnight at 4°C)

  • Detection System Comparison: Test different visualization methods (HRP Polymer vs. ABC system)

• Control Implementation Strategy:

  • Positive Tissue Control: Include human thymus sections known to express P2RY10

  • Negative Control: Use isotype-matched primary antibody on serial sections

  • Absorption Control: Pre-incubate antibody with recombinant P2RY10 to confirm staining specificity

• Technical Variables Control:

  • Batch Processing: Process all comparative samples simultaneously

  • Humidity Control: Prevent section drying during incubation steps

  • Temperature Monitoring: Maintain consistent temperatures during all incubations

• Decision-Making Algorithm:

This methodical approach allows for systematic identification and resolution of variables causing inconsistent immunohistochemistry results with P2RY10 antibodies.

What are the best strategies for analyzing conflicting flow cytometry data from P2RY10 antibody experiments?

When confronted with conflicting flow cytometry data from P2RY10 antibody experiments, employ this comprehensive analytical strategy:

• Technical Validation Assessment:

  • Instrument Performance Verification: Run fluorescence calibration beads to confirm consistent laser performance

  • Compensation Matrix Evaluation: Re-analyze compensation controls to identify spillover issues

  • Batch Effect Analysis: Compare controls across experimental batches to identify systematic variations

• Sample-Specific Investigation:

  • Viability Impact Assessment: Analyze viability dye correlations with P2RY10 signal intensities

  • Autofluorescence Characterization: Examine unstained samples across different conditions

  • Non-Specific Binding Evaluation: Compare isotype control binding patterns (Mouse IgG2B recommended)

• Experimental Design Review:

  • Positive Control Verification: Re-examine P2RY10-transfected HEK293 cell data

  • Biological Replicates Comparison: Assess consistency across biological replicates

  • Antibody Lot Comparison: Test multiple antibody lots if available

• Data Reanalysis Approach:

  • Alternative Gating Strategies: Apply multiple gating approaches and compare outcomes

  • Dimension Reduction Techniques: Use tSNE or UMAP for unbiased population identification

  • Density-Based Clustering: Apply DBSCAN or FlowSOM algorithms to identify cell populations

• Resolution Framework:

• Verification Strategy:

  • Orthogonal Method Validation: Confirm key findings using immunohistochemistry or Western blot

  • Quantitative PCR Correlation: Compare protein expression with mRNA levels

  • Independent Antibody Verification: Test with alternative clone targeting different epitope

How can I distinguish between true positive signals and artifacts when using PDE10A antibodies for neurological diagnosis?

Distinguishing between true positive signals and artifacts when using PDE10A antibodies for neurological diagnosis requires a rigorous multifaceted approach:

• Signal Pattern Authentication:

  • Characteristic Staining Pattern: Genuine PDE10A antibody reactivity produces basal ganglia-predominant synaptic staining of brain tissue

  • Anatomical Correlation: Verify that staining patterns align with known PDE10A expression in striatum-enriched regions

  • Intensity Gradient Analysis: True signals typically show physiologically relevant gradient patterns

• Methodological Cross-Validation Matrix:

• Clinical-Laboratory Correlation Assessment:

  • Clinical Syndrome Alignment: Evaluate concordance with characteristic neurological presentations

  • Response to Immunotherapy: Track antibody levels and clinical response to treatment

  • Associated Neoplasm Screening: Investigate presence of tumors known to trigger PDE10A autoimmunity

• Technical Artifact Elimination Protocol:

  • Dilution Series Testing: True antibody signals maintain pattern specificity with dilution

  • Multiple Control Implementation: Use multiple control tissues and sera (including PCA1-positive control sera)

  • Batch Processing: Include known positive and negative samples in each test batch

• Confirmation Algorithm:

  • Multiple Method Concordance: Require positive results in at least two independent methods

  • Absorption Confirmation: Demonstrate signal elimination after pre-incubation with recombinant PDE10A

  • Serial Dilution Consistency: Verify maintained signal specificity at different antibody concentrations

• Documentation Standards:

  • Capture standardized images using consistent exposure settings

  • Document all controls and technical parameters

  • Maintain blinded assessment by multiple observers when possible

This comprehensive approach enables reliable discrimination between genuine PDE10A antibody signals and technical artifacts, critical for accurate neurological diagnosis and research applications.

How can I develop a validation strategy for novel PDR10-related antibodies similar to established approaches for other immune checkpoint inhibitors?

Developing a validation strategy for novel PDR10-related antibodies requires a comprehensive approach modeled after successful validation of immune checkpoint inhibitors like anti-PD-1 antibodies:

• Multi-tiered Biochemical Characterization:

  • Binding Affinity Analysis: Determine KD values using surface plasmon resonance similar to REGN2810 characterization

  • Epitope Mapping: Identify the specific binding region and compare to established antibodies

  • Cross-reactivity Profiling: Test against related molecules to ensure specificity

  • Species Cross-reactivity Assessment: Determine binding to human and non-human primate targets for translational potential

• Functional Validation Framework:

  • Receptor Blockade Assays: Establish cell-based systems to quantify ligand-receptor blocking efficiency

  • Signal Transduction Analysis: Measure downstream signaling pathway modulation

  • Primary Cell Activation Studies: Assess effects on relevant primary immune cells (similar to REGN2810 primary T-cell assays)

  • Fc-mediated Function Assessment: Evaluate potential for ADCC/CDC activities or their absence

• Translational Model Implementation:

  • Humanized Mouse Models: Consider generating knock-in mice expressing human extracellular domains with mouse transmembrane/intracellular domains (similar to PD-1 models)

  • Ex Vivo Human Sample Testing: Validate effects on human patient-derived samples

  • Pharmacokinetic Modeling: Design studies to determine half-life and tissue distribution

• Standardized Validation Protocol Matrix:

• Regulatory-Ready Documentation Strategy:

  • Implement systematic record-keeping similar to OECD validation approaches

  • Document all validation design decisions, protocols, and acceptance criteria

  • Maintain comprehensive data trail for all validation experiments

This structured validation strategy provides a robust framework for characterizing novel PDR10-related antibodies with translational potential, ensuring comprehensive understanding of their biochemical and functional properties before advancing to clinical applications.

What are the most promising applications of P2RY10 antibodies in airway epithelial research?

P2RY10 antibodies show significant promise for advancing airway epithelial research through several innovative applications:

• Signaling Pathway Dissection:

  • TACE-EGFR-ERK Pathway Analysis: P2RY10 antibodies can help elucidate the receptor-independent mechanisms of lysophosphatidylserine-induced MUC5AC production in airway epithelial cells

  • Feedforward Regulation Investigation: Utilize antibodies to track protein expression changes during feedforward regulatory mechanisms

  • Receptor-Independent Signaling Studies: Employ antibodies to distinguish between canonical and non-canonical signaling pathways

• Chronic Airway Disease Research Applications:

  • Asthma Pathophysiology Studies: Investigate P2RY10 expression patterns in asthmatic vs. normal airway epithelium

  • COPD Progression Markers: Evaluate P2RY10 as a potential biomarker for disease progression

  • Therapeutic Target Validation: Use antibodies to assess P2RY10 blockade effects on mucus hypersecretion

• Specialized Experimental Approaches:

  • Single-Cell Analysis: Combine P2RY10 antibodies with flow cytometry for heterogeneity assessment in airway epithelial populations

  • Live Cell Imaging: Develop non-disruptive labeling techniques to track receptor dynamics

  • Co-localization Studies: Use P2RY10 antibodies alongside markers of cellular compartments to determine receptor trafficking patterns

• Translational Research Applications:

  • Patient-Derived Organoid Models: Apply antibodies to characterize receptor expression in 3D airway epithelial organoids

  • Precision Medicine Approaches: Stratify patient samples based on receptor expression patterns

  • Biomarker Development: Validate P2RY10 as a diagnostic or prognostic marker in airway diseases

• Methodological Innovation Framework:

  • Multiplexed Imaging Systems: Combine P2RY10 antibodies with other markers for comprehensive tissue architecture analysis

  • Receptor Trafficking Assays: Develop antibody-based systems to track internalization and recycling

  • Proximity Ligation Approaches: Identify protein-protein interactions involving P2RY10 in situ

This multifaceted approach leverages P2RY10 antibodies to address fundamental questions in airway epithelial biology while simultaneously advancing potential clinical applications in respiratory medicine.

How might PDE10A antibodies contribute to understanding the intersection of neurological autoimmunity and cancer biology?

PDE10A antibodies offer unique opportunities to investigate the complex relationship between neurological autoimmunity and cancer biology through several innovative research approaches:

• Paraneoplastic Mechanism Elucidation:

  • Tumor Expression Profiling: Use PDE10A antibodies to screen diverse tumor types for ectopic PDE10A expression

  • Immune Response Characterization: Analyze the development of PDE10A autoantibodies in relation to tumor immunogenicity

  • Cross-reactivity Analysis: Investigate epitope similarities between tumor-expressed and neural PDE10A

• Translational Research Framework:

  • Early Cancer Detection Biomarkers: Evaluate PDE10A antibodies as potential early indicators of occult malignancies

  • Predictive Response Markers: Assess whether antibody titers correlate with tumor therapy response

  • Neurological Protection Strategies: Develop interventions targeting the autoimmune component while preserving anti-tumor immunity

• Integrated Experimental Approaches:

  • Patient-Derived Xenograft Models: Create models expressing both tumor and neuronal PDE10A to study cross-reactivity

  • Immune Cell Repertoire Analysis: Characterize T and B cell responses specific to PDE10A epitopes

  • Blood-Brain Barrier Penetration Studies: Investigate mechanisms allowing antibody access to CNS targets

• Clinical-Molecular Correlation Matrix:

• Emerging Technology Integration:

  • Single-Cell Sequencing: Characterize B cell receptor repertoires in patients with PDE10A antibodies

  • Spatial Transcriptomics: Map PDE10A expression in tumor microenvironments

  • Computational Modeling: Predict cross-reactive epitopes between tumor and CNS PDE10A

This comprehensive research strategy leverages PDE10A antibodies as powerful tools to illuminate the bidirectional relationship between cancer immunobiology and neurological autoimmunity, potentially leading to novel diagnostic approaches and therapeutic interventions for paraneoplastic neurological syndromes.